Tango Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Tango Therapeutics (TNGX).

Price Target Range — 12 Quarters

Analyst Consensus — 14 Analysts

13Buy

1Hold

Consensus RatingBuy# Analysts14Avg. Consensus PT$37Upside to Avg. PT+64.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 29, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$68
Oct 16, 2026	William Blair	Alethia Young	Initiate	Outperform	—
Aug 18, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$66→$68
Aug 12, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$32→$35
Jul 17, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$36→$40
Jul 15, 2026	JP Morgan	Brian Cheng	Initiate	Overweight	$46
Jun 29, 2026	Canaccord Genuity	John Newman	PT Raise	Buy	$42→$46
Jun 26, 2026	Jefferies	Maury Raycroft	Upgrade	Hold→Buy	$27→$60
Jun 11, 2026	Canaccord Genuity	John Newman	Maintained	Buy	$42
Jun 9, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$27→$66
Jun 9, 2026	Canaccord Genuity	John Newman	PT Raise	Buy	$30→$42
Jun 8, 2026	Leerink Partners	Andrew Berens	PT Raise	Outperform	$55→$69
May 15, 2026	Piper Sandler	Kelsey Goodwin	Downgrade	Overweight→Neutral	$16→$24
May 15, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$20→$30
May 14, 2026	Jefferies	Maury Raycroft	Downgrade	Buy→Hold	$18→$27
May 14, 2026	Leerink Partners	Andrew Berens	PT Raise	Outperform	$28→$55
May 14, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$19→$33
Apr 27, 2026	Stifel	Laura Prendergast	PT Raise	Buy	$24→$40
Apr 2, 2026	Canaccord Genuity	John Newman	Initiate	Buy	$30
Mar 11, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$19→$20

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $68 price target.

Benzinga Newsdesk

PRO
William Blair Initiates Coverage On Tango Therapeutics with Outperform Rating

William Blair analyst Alethia Young initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Outperform rating.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68

HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $66 to $68.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $35

Guggenheim analyst Michael Schmidt maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $32 to $35.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $40

Mizuho analyst Joseph Catanzaro maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $36 to $40.

Benzinga Newsdesk

This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and TNGX with positive ratings and price targets.

Avi Kapoor

Tango Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Tango Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target

PRO
William Blair Initiates Coverage On Tango Therapeutics with Outperform Rating

PRO
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68

PRO
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $35

PRO
Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $40

This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

People Also Watch

People Also Watch

Tango Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Tango Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target

PROWilliam Blair Initiates Coverage On Tango Therapeutics with Outperform Rating

PROHC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68

PROGuggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $35

PROMizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $40

This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target

PRO
William Blair Initiates Coverage On Tango Therapeutics with Outperform Rating

PRO
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68

PRO
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $35

PRO
Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $40